![\"Biotecnologie\"](\"https:\/\/www.esteri.it\/wp-content\/uploads\/2026\/03\/biotecnologie-maeci.webp\")
<\/p>\n<\/p>\n
<\/p>\n
The Ministry of Foreign Affairs and International Cooperation and Office IV<\/strong> of the Directorate General for Growth and Export Promotion<\/em> have launched a series of strategic actions<\/strong> aimed at promoting international dialogue on opportunities for growth and development within the life sciences and biotechnology ecosystem<\/strong>, while strengthening cooperation between the public and private sectors.<\/p>\n Italy <\/strong>can rely on one of the richest and most dynamic life sciences ecosystems<\/strong> in Europe, thanks to the presence of numerous universities, technology transfer hubs, research centres, clinical and experimental hospitals, incubators, accelerators, major industrial groups, SMEs and startups.<\/p>\n In 2024<\/strong>, companies operating in the biotech sector generated an estimated total turnover of EUR 53.4 billion<\/strong>, marking a 5% increase compared with 2023<\/strong>.<\/p>\n This represents an important driver of competitiveness for Italy<\/strong>, and MAECI<\/strong> plays a key role in strengthening the international positioning<\/strong> of the sector. On the one hand, it promotes exports<\/strong> through diplomatic initiatives, strategic alliances and participation in trade fairs and conferences<\/strong>; on the other, internationalisation policies and scientific innovation facilitate access to foreign markets and help preserve the sector\u2019s competitiveness.<\/p>\n A Working Group on the internationalisation of industries in the biotechnology sector<\/strong><\/a> has been established at the Ministry of Foreign Affairs, in agreement with MIMIT, MUR, the Italian Trade Agency, the CNR and other institutional stakeholders, as well as representatives from the research community, trade associations and the financial sector.<\/p>\n The Final Report of the 2024\u20132025 Working Group<\/strong><\/a> sets out a strategy aimed at improving the competitiveness of the Italian biotechnology sector by supporting the internationalisation of Emerging Biotechnology Companies<\/strong> and strengthening their research and development activities<\/strong>. More specifically, the Working Group identified the emerging biotechnologies best suited to addressing diseases of national interest<\/strong>, as well as bio-industrial and environmental priorities<\/strong>, including with a view to consolidating the circular bioeconomy<\/strong>.<\/p>\n In order to support faster internationalisation, the members of the Working Group recommended the establishment of a Special Register of Emerging Biotechnology Companies (ESIBE)<\/strong>, in both the healthcare and industrial-environmental fields, together with internationalisation programmes designed to support networking with potential investors, institutions and international partners. Lastly, in order to prevent companies from relocating abroad, the Report proposes a refocusing of the Italian venture capital system<\/strong>, with stronger support for strategic investments capable of fostering the development and growth of biotechnology companies in Italy.<\/p>\n Montalcini Global Biotech Tour<\/strong><\/p>\n Together with the Italian Trade Agency<\/strong>, the existing Life Sciences and Biotech promotional programme has been strengthened and the Montalcini Global Biotech Tour<\/strong> has been launched, by adding further stops and branding those already scheduled.<\/p>\n The programme includes participation in the leading global biotech events,<\/strong> together with initiatives aimed at fostering networking opportunities and relations with potential investors.<\/p>\n The objective is to enhance national assets in the biotech sector more effectively, through a more organic presentation of the so-called \u201cItalian Biotech Country System<\/strong>\u201d, to be promoted through the diplomatic-consular network and the offices of the Italian Trade Agency.<\/p>\n Thanks to the work of Office IV of the DGCE<\/strong>, in 2025 the Tour was launched in San Francisco<\/strong> on the occasion of the JP Morgan Healthcare Conference<\/strong> (15 January 2025) and included the following stops: Doha<\/strong> \u2014 event organised by the Embassy of Italy and the Italian Trade Agency; Basel<\/strong> \u2014 on the sidelines of Swiss Biotech Day (5 May 2025); Boston<\/strong> \u2014 on the occasion of BIO USA (16\u201319 June 2025); and Vienna<\/strong> \u2014 during BIO Europe<\/strong> (3\u20135 November 2025).<\/p>\n 2026 Programme<\/strong><\/p>\n The following international programme is scheduled for 2026:<\/p>\n San Francisco (USA)<\/strong> \u2013 JPMorgan Healthcare Conference, 12\u201315 January 2026 <\/p>\n Last updated: January 2026<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" The Ministry of Foreign Affairs and International Cooperation and Office IV of the Directorate General for Growth and Export Promotion have launched a series of strategic actions aimed at promoting international dialogue on opportunities for growth and development within the life sciences and biotechnology ecosystem, while strengthening cooperation between the public and private sectors. […]","protected":false},"author":1,"featured_media":0,"parent":181993,"menu_order":20,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-182040","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/pages\/182040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/comments?post=182040"}],"version-history":[{"count":3,"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/pages\/182040\/revisions"}],"predecessor-version":[{"id":182346,"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/pages\/182040\/revisions\/182346"}],"up":[{"embeddable":true,"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/pages\/181993"}],"wp:attachment":[{"href":"https:\/\/www.esteri.it\/en\/wp-json\/wp\/v2\/media?parent=182040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nSan Diego (USA)<\/strong> \u2013 BIO USA, 22\u201325 June 2026
\nSingapore<\/strong> \u2013 Asia Bio Partnering Forum, 1\u20132 September 2026
\nCologne (Germany)<\/strong> \u2013 BIO Europe, 9\u201311 November 2026
\nDubai (UAE)<\/strong> \u2013 ARABLAB LIVE 2026, October 2026
\nRiyadh (Saudi Arabia)<\/strong> \u2013 GLOBAL HEALTH 2026, October 2026
\nRiyadh (Saudi Arabia)<\/strong> \u2013 BIO MIDDLE EAST 2026, May 2026
\nHouston (USA)<\/strong> \u2013 A possible business mission, planned for the second half of 2026, will focus on biotech startups and investment attraction, with possible synergies with the Global Startup Program<\/a> and INNOVIT<\/a>, with a view to establishing structured partnerships with TMC (Texas Medical Center).
\nDoha (Qatar)<\/strong> \u2013 The participation of Italian biotech companies in the Business Forum<\/strong> scheduled for May 2026<\/strong> is currently being organised.<\/p>\n